CE Mark for BlastX antimicrobial wound gel.- Next Science.

Next Science receives CE Mark approval for BlastX wound gel. This approval allows Next Science to apply to sell BlastX in each market in the European Union and the UK. BlastX is the second Next Science product to receive a CE Mark, with Bactisure (distributed by Zimmer Biomet globally) receiving a CE Mark in March this year. The BlastX antimicrobial wound gel is based on Next Science’s patented, non-toxic, biofilm- disrupting Xbio technology. BlastX deconstructs the bacterial biofilm, the gel envelops and eliminates the bacteria and defends from recolonisation while maintaining a moist wound environment conducive to healing. The product is ideal for the treatment of non-healing wounds (Chronic Wounds) such as diabetic foot ulcers, bed sores (pressure ulcers) and venous leg ulcers as well as preventing infections in acute wounds and surgical wounds. Chronic Wounds continue to be a major health issue for patients in all countries in the world. They are very difficult to treat, increase pain and suffering, cause a decline in quality of life and increase mortality. BlastX was FDA approved in 2017 and is distributed in the US by 3M Company.